On Thursday, SK bioscience announced the reshuffling of its departments and the appointment of Kim Joon-mo, a former Pfizer executive, to vice president.

Starting from Dec.13, the company will operate six departments, namely Business Development (BD), Bio Research, Development, L HOUSE Factory, Quality, and Management Support.

The objective of the reorganization is to establish each department as a responsible management system, enhancing business advancement and expertise, according to the company.

Each of the six departments will take on specialized functions. The BD Department will focus on constructing business portfolios and cultivating international partnerships. The Bio Research Department will lead the advancement of the product portfolio on a global scale. The Development Department will spearhead clinical, development, and licensing activities within the R&D process. The L HOUSE Factory Department and the Quality Department will manage the production of commercial products and oversee global quality management. The Management Support Department will supervise corporate strategy, new business development and investment, and finance.

Additionally, SK bioscience has established a new Quality Excellence Office within the Quality Department. The QE Office will spearhead initiatives for quality improvement, aiming to align product production processes at the L-House, a vaccine plant in Andong, North Gyeongsang Province, and the Songdo Global R&D Center (anticipated completion in 2025), with the U.S. Good Manufacturing Practices (cGMP) standards.

Kim Joon-mo, the newly appointed vice president, will lead the QE Office. With over two decades of experience, Kim has played pivotal roles in production and quality improvement within global biotechnology companies. His previous positions include Product Process Management at Pfizer in the U.S., Site Investigation at Pfizer in APAC Singapore, and Operational Excellence Lead at Legend Biotech, a biotechnology company in New Jersey, according to SK bioscience.